Pentagon opens wallet for biotech firms with minimal public oversight
H.R. 5187 — To establish in the Department of Defense a program to support the expansion of domestic bioindustrial manufacturing capacity. · Filed by Ro Khanna (D-CA) · 2 cosponsors · Introduced Sep 8, 2025 · Referred to committee
Your members of Congress
Enter a ZIP to see where your representative and both senators stood on this bill.
Looked up on this device — your ZIP is never stored on our servers.
What it does
This bill directs the Department of Defense to create a competitive grant program awarding federal funds to private companies that build, upgrade, or retool factories to manufacture biological products (chemicals, materials, drugs) at scale. The goal is to strengthen domestic supply chains for military-relevant biotech products and reduce dependence on foreign sources. Winners are chosen based on their technology's military value, geographic distribution, and ability to supply the Pentagon.
Why we flagged it
The bill establishes a federal grant program explicitly designed to subsidize private biomanufacturing companies on the basis of military utility and supply-chain resilience. While framed as national security, it is functionally a targeted industrial subsidy with weak public-interest safeguards.
What the text implies
- No requirement that award recipients sell products to the public or at regulated prices; Pentagon contracts may be the sole customer, creating a captive market for private firms at taxpayer expense.
- Award criteria emphasize military capability and warfighter needs, not civilian health outcomes or public health preparedness, despite biotech's dual-use potential.
The full analysis lists 5 implications of this text.
Who stands to gain
biopharmaceutical manufacturers; biotech contract manufacturers; specialty chemical producers